Xoifeb 40 Tablet contains Febuxostat 40 mg, a xanthine oxidase inhibitor indicated for the management of hyperuricemia in patients with gout. Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for converting hypoxanthine to xanthine and subsequently to uric acid, thereby reducing serum uric acid levels. This reduction helps prevent gout attacks and the formation of urate crystals in joints and tissues. Xoifeb 40 is typically prescribed for patients who are intolerant to or inadequately managed with allopurinol. The tablet is administered orally, usually once daily, with or without food, and dosage adjustments may be necessary based on renal function and therapeutic response. Common adverse effects include liver function abnormalities, nausea, rash, and joint pain. Liver enzymes should be monitored periodically during treatment. Febuxostat is contraindicated in patients with hypersensitivity to the drug and should be used with caution in those with cardiovascular disease due to a potential increased risk of cardiovascular events. Patients should be advised to maintain adequate hydration to prevent kidney stone formation. Xoifeb 40 Tablet offers an effective option for long-term urate-lowering therapy in gout management under appropriate medical supervision.